SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 57.23+0.4%2:15 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (1602)9/12/2000 3:10:58 PM
From: greedsgd_2000  Read Replies (1) of 52153
 
"EMERGING" biotechs the target for CALPERS.

1. with smaller caps (e.g NMPS, approx 200 mil cap)- these amounts would matter much more.
2. HGSI (8.5 billion cap) may not be an "emerging" biotech via CALPERS guidelines.
3. BELLWEATHER STATUS of CALPERS - its not the amount that is so important, instead its the concept of a key pension fund making biotechs a significant core investment. I expect others to follow.
4. The follow on offerings while stock and sector dilutive -are usually precisely the cash necessary to finish Phase 2 and Phase 3 programs - and get products before the FDA. Cash flows will start to build sometime next yr as this first backlog of biotechs products starts to hit the market.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News